Details for Patent: 9,173,851

« Back to Dashboard

Which drugs does patent 9,173,851 protect, and when does it expire?

Patent 9,173,851 protects PROCYSBI and is included in two NDAs.

Protection for PROCYSBI has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-six patent family members in twenty-three countries.

Summary for Patent: 9,173,851

Title:	Delayed release cysteamine bead formulation, and methods of making and using same
Abstract:	An enteric-coated bead dosage form of cysteamine, and related methods of manufacture and use, are disclosed.
Inventor(s):	Kathlene Powell, Ramesh Muttavarapu
Assignee:	Horizon Therapeutics US Holding LLC
Application Number:	US14/751,639
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,173,851
Patent Claim Types: see list of patent claims	Composition; Formulation; Compound; Dosage form;

Drugs Protected by US Patent 9,173,851

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Horizon	PROCYSBI	cysteamine bitartrate	CAPSULE, DELAYED RELEASE;ORAL	203389-001	Apr 30, 2013		RX	Yes	No					Y
Horizon	PROCYSBI	cysteamine bitartrate	CAPSULE, DELAYED RELEASE;ORAL	203389-002	Apr 30, 2013		RX	Yes	Yes					Y
Horizon	PROCYSBI	cysteamine bitartrate	GRANULE, DELAYED RELEASE;ORAL	213491-001	Feb 14, 2020		RX	Yes	No					Y
Horizon	PROCYSBI	cysteamine bitartrate	GRANULE, DELAYED RELEASE;ORAL	213491-002	Feb 14, 2020		RX	Yes	Yes					Y

International Family Members for US Patent 9,173,851

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	096628
Argentina	128816
Australia	2014281702
Brazil	112015031417
Canada	2914770